Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.55B 16.29B 14.97B 28.21B 1,932B 28.62B 194B 75.95B 946B 75.18B 73.56B 3,266B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.92B 17.57B 16.14B 30.42B 2,084B 30.87B 209B 81.91B 1,020B 81.07B 79.32B 3,523B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.37%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
118.72
10 years 11.96
Extreme 11.96
159.54
Date Insider Type Main position Quantity % Market Cap.
3/23/26 Free

Executive/Senior Manager

199,374 0.1044%
3/23/26 Issuer sale

Director

57,962 0.0304%
3/23/26 Free

Chief Financial Officer

261,465 0.1370%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+116.94%+10.40% 20.03B
-3.01%-3.12%+145.24%+109.35% 4.75B
-10.92%-4.37%+107.98%+180.77% 3.61B
-6.30%+7.91%+63.42%-30.60% 2.45B
+2.01%+3.82%-26.08%-35.34% 2.08B
-2.21%+26.89%+189.94%+262.63% 1.99B
-0.63%+0.21%+178.85%-43.47% 1.05B
-1.10%-2.71%-13.50%+25.12% 837M
-0.14%+1.86%-36.72%-14.16% 495M
+1.01%-14.96%-16.59% - 402M
Average -1.28%+5.74%+70.95%+51.63% 3.77B
Weighted average by Cap. -0.64%+5.18%+107.50%+46.23%

Financials

2024 2025
Net sales 2.76B 2.42B 2.24B 2.06B 3.89B 266B 3.94B 26.73B 10.46B 130B 10.36B 10.13B 450B 3.25B 2.85B 2.64B 2.43B 4.57B 313B 4.64B 31.46B 12.31B 153B 12.19B 11.93B 530B
Net income -1.03B -901M -837M -769M -1.45B -99.28B -1.47B -9.97B -3.9B -48.58B -3.86B -3.78B -168B -208M -182M -169M -155M -293M -20.07B -297M -2.02B -789M -9.82B -781M -764M -33.92B
Net Debt 1.74B 1.52B 1.41B 1.3B 2.45B 168B 2.48B 16.84B 6.59B 82.05B 6.52B 6.38B 283B 1.57B 1.38B 1.28B 1.17B 2.21B 152B 2.24B 15.21B 5.95B 74.14B 5.89B 5.77B 256B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock